Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor
As the most common gene mutation found in cancers, p53 mutations are detected in up to 96% of high-grade serous ovarian carcinoma (HGSOC). Meanwhile, mutant p53 overexpression is known to drive oncogenic phenotypes in cancer patients and to sustain the activation of EGFR signaling. Previously, we ha...
Main Authors: | Zih-Yin Lai, Kai-Yun Tsai, Shing-Jyh Chang, Yung-Jen Chuang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/16/8784 |
Similar Items
-
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
by: Andrea Forschner, et al.
Published: (2020-02-01) -
Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium
by: Markowski Dominique N, et al.
Published: (2012-01-01) -
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
by: Johanna Huun, et al.
Published: (2017-04-01) -
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020-07-01) -
MDM2 inhibitor ameliorates cisplatin‐induced nephropathy via NFκΒ signal inhibition
by: Tomoyuki Fujikura, et al.
Published: (2019-02-01)